Late steroid-induced ocular hypertension after intravitreal dexamethasone implants: A series of 20 cases

• Published in: Journal francais d'ophtalmologie Vol. 46; no. 9; p. 1039
• Main Authors: Billant, J, Douma, I, Agard, E, Levron, A, Bouvarel, H, Leroux, P, Badri, Y, Dot, C
• Format: Journal Article
• Language: English; French
• Published: France 01-11-2023
• Subjects: Adult; Aged; Aged, 80 and over; Dexamethasone - administration & dosage; Dexamethasone - adverse effects; Drug Implants - adverse effects; Female; Glucocorticoids - administration & dosage; Glucocorticoids - adverse effects; Humans; Intraocular Pressure - drug effects; Intravitreal Injections; Male; Middle Aged; Ocular Hypertension - chemically induced; Retrospective Studies; Time Factors; Dexamethasone intravitreal implant (DEXi); Late steroid-induced ocular hypertension; Hypertonie oculaire cortisonique tardive; Hypertonie oculaire (HTO); Ocular hypertension (OHT); Implant intravitréen de dexaméthasone (DEXi)
• ISSN: 1773-0597
• DOI: 10.1016/j.jfo.2023.03.041

Steroid-induced ocular hypertension (OHT) occurs in approximately one third of cases after dexamethasone implant (DEXi) injection. Among these, more than one fifth occur after the third DEXi intravitreal injection (IVI). Our goal was to analyze the clinical profiles of these late responders.
A real-life, retrospective, observational study was conducted to assess demographic characteristics and intraocular pressure (IOP) responses in late responders (IOP ≥ 21mmHg, n DEXi ≥ 4). The following parameters were analyzed: IOP 2 months after IVI and number of glaucoma medications needed. The IOP response compared to baseline was defined as low (< +6mmHg), moderate (≤ +15mmHg) or high (> 15mmHg).
Late steroid-induced OHT occurred in 20.8% of cases. Twenty eyes (18 patients) were included. The mean duration of follow-up was 3.8±1.9 years. They received a mean number of 9.5±4.2 IVI. The first OHT peak, measured at 25.3±3.2mmHg (21-31), occurred after 6.8±2.3 IVI. Approximately 65% of OHT spikes occurred between the fourth and sixth IVI; 35% occurred later. At maximum, 1.7±1.0 glaucoma medications and 0.75±0.79 SLT procedures were required to control the OHT, with no filtering surgery required. The ratio of "low," "moderate," and "high" responders was 5%, 85% and 10% respectively.
Late steroid-induced OHT occurs after at least 3 DEXi in one fifth of multi-injected patients, requiring long-term IOP monitoring. This case series identifies mostly moderate responder profiles, whose IOP rise often remains well-controlled with medical management or laser treatment (SLT).